Laura M. Periman, MD, discusses her key points regarding the benefits of using intense pulsed light (IPL)therapy to treat chalazion.
Harvey Fishman, MD, PhD, shares why intense pulsed light (IPL) therapy does wonders for his dry eye patients. Listen below!
In our latest episode, we discuss how to market your practice to draw in profitable new patients with Donna Suter, president of Donna Suter Consulting. Donna is an ophthalmic practice management expert with more than 20 years of expertise.
If you have a product idea, no matter how simple or elaborate, just go for it! You never know where it will lead you, says Joshua Mali, MD.
The latest podcast features a discussion with ARVO Executive Director Iris Rush, who discusses the upcoming annual conference.
After spending years encouraging and helping train colleagues to treat floaters, Christopher F. Wood, MD, is confident that the technologies available today will allow ophthalmologists to safely popularize the procedure and expand access to many more patients.
Whenever there’s market volatility, investors naturally become concerned about what they should do to help protect their portfolios. Ophthalmology Times' contributor John S. Grande, CFP, talks about thinking long term, and how investors may use volatility to their advantage.
In Part 2 of this EyePod episode, Rohit Varma, MD, continues the discussion on artificial intelligence (AI) and its increasing presence in diabetic retinopathy (DR) and glaucoma—and at the podium
Listen to Part 1 of our interview with Rohit Varma, MD, founding director of the newly formed Southern California Eyecare and Vision Research Institute, on artificial intelligence (AI) and its impact on the practice of ophthalmology. Why AI now, and why ophthalmology?
Nir Israeli, CEO of Sanoculis, explains the newest advances in glaucoma devices from the company.
Ahmad Aref, MD, talks about the newest glaucoma device advances from New World Medical Inc.
Chris Pulling, MicroOptx CEO, explains the newest advancements in glaucoma devices from the company.
Russ Trenary, InnFocus CEO and President, explains the newest advancements in glaucoma devices from Innfocus.
Morgan Fedorchak, PhD, discusses recent data and findings from Selkie Therapeutics.
Barbara Wirostko, MD, presents data from Ohr Pharmaceutical Inc.